Korea's InCerebro to leverage AI to identify drug candidates

South Korean AI-based drug developer InCerebro aims to identify potential drug candidates using molecular modeling technology, according to its CEO Cho Eun-sung.

Speaking at an AI new drug development project briefing held in Seoul on Monday, Cho stated that his company plans to leverage AI's ability to predict protein structures to develop new drugs through a combination of molecular modeling and AI technologies.

Molecular modeling technology, which predicts protein action and structure through molecular physics and AI deep learning, is regarded as a promising approach in the pharmaceutical and bio industries for developing vaccines and treatments.

InCerebro's Modeling with Intelligence for Novel Drugs (MIND) platform incorporates AI technologies, molecular modeling, and quantum mechanics, and represents a comprehensive computational drug discovery platform.

Write to Jeong Min Nam at peux@hankyung.com